CLAIMS

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof; wherein,

L is $-\overset{*}{C}(O)-(CH_2)_m-(X-\underset{R_c}{CH}-CH_2)_n-NH-$, wherein the -C(O)- group marked with * is connected to the nitrogen bearing R_3 in Formula (I);

X is CH_2, O, NH, or S;

R_1, R_2 and R_6 are each independently a side chain of an amino acid, hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl or (C_2-C_6)alkynyl; wherein each (C_1-C_6)alkyl, (C_2-C_6)alkenyl or (C_2-C_6)alkynyl is optionally substituted by one or more substituents selected from hydroxy, amino, amido, alkylamino, acylamino, -$(CH_2)_m$-COOH, -$(CH_2)_m$-COO-alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, guanidino, (cycloalkyl)alkyl, (heterocyclyl)alkyl, (heteroaryl)alkyl, -SH and -S-(alkyl); optionally wherein cycloalkyl, aryl, heterocyclyl and heteroaryl are further substituted by one or more substituents such as hydroxy, alkoxy, halo, amino, nitro, cyano or alkyl; optionally wherein two or three carbon atoms of the (C_1-C_6)alkyl, (C_2-C_6)alkenyl or (C_2-C_6)alkynyl form part of a 3-7-membered carbocyclic, or heterocyclic ring (such as a cyclobutyl or oxirane ring);

R_1', R_2', R_3 and R_5 are each independently hydrogen, or alkyl;

or R_1 and R_1', together with the carbon atom to which they are attached, form an optionally substituted cycloalkyl or heterocycloalkyl ring;

or R_1 and R_3, together with the atoms to which they are attached, form a heterocyclic ring, optionally substituted with one or more groups independently selected from amino, cyano, alkyl, halo and hydroxy;

or R_2 and R_2', together with the carbon atom to which they are attached form an optionally substituted cycloalkyl, or heterocycloalkyl ring;

or R_2 and R_5, together with the atoms to which they are attached form a heterocyclic ring, optionally substituted with one or more groups independently selected from amino, cyano, alkyl, halo and hydroxy;

R_4 and R_4' independently are hydrogen, or alkyl;

R_a and R_a' are each hydrogen; or together represent an oxo (=O) group;

R_b and R_b' are each hydrogen; or together represent an oxo (=O) group;

R_c at each occurrence is independently hydrogen or alkyl;

m is an integer from 0 to 3;

n, independently for each occurrence, is an integer from 2 to 20;

r is an integer from 0 to 20; and

with a proviso that R_6 is not a side chain of Ser, Asp, Ala, Ile, Phe, Trp, Lys, Glu and Thr, when, R_1 is a side chain of Ala, Ser, Thr or Leu, R_2 is a side chain of Asp, Asn, Glu or Gln and R_5 and R_c are hydrogen.

2. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, wherein the compound of formula (I) is a compound of formula (IB):



or a pharmaceutically acceptable salt thereof.

4. The compound of claims 1 to 3, wherein the compound of formula (I) is a compound of formula (IC):



or a pharmaceutically acceptable salt thereof; wherein,

R_1, R_2 and R_6 are each independently a side chain of an amino acid or hydrogen; and

R_5 is hydrogen or alkyl.

5. The compound according to claim 1, wherein,

R_1 is a side chain of Ser, Tyr, Ile, Asp, Lys, Phe, Asn, Gln, Glu, Trp, His, Arg, Val or Thr;

R_2 is a side chain of Asp, Asn, Ile, Lys, Phe, Ser, Thr, Val or Glu;
R_1' and R_2' are each hydrogen;
R_3, R_4, R_4' and R_5 are each independently hydrogen;
R_6 is a side chain of Ser, Leu, Tyr, Lys, Asp, Asn, Glu, Gln, Val or Thr;
both R_a and R_a' together represent an oxo (=O) group;
both R_b and R_b' together represent an oxo (=O) group;
L is $-C(O)-(CH_2)_m-(X-CH_2-CH_2)_n-NH-$;
X is O;
m is an integer from 0 to 3; and
n, independently for each occurrence, is an integer from 2 to 20;
or a pharmaceutically acceptable salt thereof.

6. The compound according to any one of claims 1 to 4, wherein R_1 is $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, or $(C_2$-$C_6)$alkynyl; wherein $(C_1$-$C_6)$alkyl, $(C_2$-$C_6)$alkenyl, and $(C_2$-$C_6)$alkynyl are optionally substituted by one or more substituents selected from hydroxy, amino, amido, alkylamino, acylamino, $-(CH_2)_m$-COOH, $-(CH_2)_m$-COO-alkyl, cycloalkyl, heterocyclyl, heteroaryl, guanidino, (cycloalkyl)alkyl, (heterocyclyl)alkyl, (heteroaryl)alkyl, and (alkyl)-S.

7. The compound according to the claim 6, wherein R_1 is $(C_1$-$C_6)$alkyl, optionally substituted by cycloalkyl or -S-(alkyl).

8. The compound according to any one of claims 1 or 3, wherein R_1 and R_1' together with the carbon atom to which they are attached form cycloalkyl ring; wherein the cycloalkyl is cyclopentyl or cyclohexyl.

9. The compound according to any of claims 1 to 4, wherein R_2 and R_5 together with the atoms to which they are attached, form a heterocyclic ring; wherein the heterocyclic ring is pyrrolidine.

10. A compound selected from:

Comp. No.	Structure	Comp. No.	Structure
1.		2.	
3.		4.	
5.		6.	
7.		8.	

9.		10.	
11.		12.	
13.		14.	
15.		16.	
17.		18.	

19.		20.	

and or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound of any one of claims 1-10 and a pharmaceutically acceptable carrier or excipient.

12. Use of a compound of any one of claims 1-10 in the manufacture of a medicament for the treatment of cancer.

13. Use of a compound of any one of claims 1-10 in the manufacture of a medicament for the treatment of a bacterial infection, a viral infection, a fungal infection, or an immunological condition in a subject.

14. The use of claim 12, wherein the cancer is selected from lung cancer, breast cancer, colon cancer, renal cancer, bladder cancer, thyroid cancer, prostate cancer, osteosarcoma, and Hodgkin’s lymphoma.